x

Science

Novavax COVID-19 Vaccine Works, But Less so Against Variants

January 29, 2021

Novavax Inc. said Thursday that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new mutated versions of the virus circulating in that country and South Africa.

The announcement comes amid worry about whether a variety of vaccines being rolled out around the world will be strong enough to protect against worrisome new variants – and as the world desperately needs new types of shots to boost scarce supplies.

The study of 15,000 people in Britain is still underway. But an interim analysis found 62 participants so far have been diagnosed with COVID-19 – only six of them in the group that got vaccine and the rest who received dummy shots.

The infections occurred at a time when Britain was experiencing a jump in COVID-19 caused by a more contagious variant. A preliminary analysis found over half of the trial participants who became infected had the mutated version. The numbers are very small, but Novavax said they suggest the vaccine is nearly 96% effective against the older coronavirus and nearly 86% effective against the new variant. The findings are based on cases that occurred at least a week after the second dose.

"Both those numbers are dramatic demonstrations of the ability of our vaccine to develop a very potent immune response," Novavax CEO Stanley Erck said in a call with investors late Thursday.

Scientists have been even more worried about a variant first discovered in South Africa that carries different mutations. Results from a smaller Novavax study in that country suggests the vaccine does work but not nearly as well as it does against the variant from Britain.

The South African study included some volunteers with HIV. Among the HIV-negative volunteers, the vaccine appears 60% effective. Including volunteers with HIV, overall the protection was 49%, the company said. While genetic testing still is underway, so far about 90% of the COVID-19 illnesses found in the South African study appear due to the new mutant.

"These are good results. There is reason to be optimistic" about the 60% effectiveness, said Glenda Gray, head of the South African Medical Research Council. Even against the new variant that now causes more than 90% of new cases in that country, "we're still seeing vaccine efficacy," she said.

More concerning is what the study showed about a totally different question — the chances of people getting COVID-19 a second time, said the leader of the South African study, Shabir Madhi of the University of the Witwatersrand in Johannesburg. Tests suggested that nearly a third of study participants had been previously infected, yet rates of new infections in the placebo group were similar. 

"Past infection with early variants of the virus in South Africa does not protect" against infection with the new one, he said. "There doesn't seem to be any protection derived."

Novavax said it needs some additional data before it can seek British authorization for the vaccine's use, sometime in the next month or so. A larger study in the U.S. and Mexico has enrolled slightly over half of the needed 30,000 volunteers. Novavax said it's not clear if the Food and Drug Administration will need data from that study, too, before deciding whether to allow U.S. use.

Meanwhile, it is starting to develop a version of the vaccine that could more specifically target the mutations found in South Africa, in case health authorities eventually decide that updated dosing is needed.

Vaccines against COVID-19 train the body to recognize the new coronavirus, mostly the spike protein that coats it. But the Novavax candidate is made differently than the first shots being used. Called a recombinant protein vaccine, the Maryland company uses genetic engineering to grow harmless copies of the coronavirus spike protein in insect cells. Scientists extract and purify the protein and then mix in an immune-boosting chemical.

RELATED

FORT LAUDERDALE, Fla. (AP) — South Florida researchers trying to prevent predatory fish from devouring laboratory-grown coral are grasping at biodegradable straws in an effort to restore what some call the rainforest of the sea.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

Video

New York Greek Independence Parade Honors 1821 and Grim Anniversary for Cyprus (Vid & Pics)

NEW YORK – The New York Greek Independence Parade on Fifth Avenue, commemorating the 203rd anniversary of the Greek Revolution of 1821, was held in an atmosphere of emotion and pride on April 14.

A plot of land for sale in Tripoli, Arkadia Prefecture, 268.

ATHENS - Expecting another record year in tourism to surpass the numbers in 2023 in arrivals and revenues, Greece’s infrastructure - particularly on overwhelmed islands - isn’t adequate to deal with the demands even as more resorts keep opening.

For years, Israel and Iran have been engaged in a silent struggle of mutual annihilation.

ATHENS – The Ilias Lalaounis Jewelry Museum (ILJM) Jewelry Artist in Residence Program (JaIR) accepts applications throughout the year.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.